Converging Market Stimulators and Inhibitors May Cause a Market Decline of 13.6% by 2012 in the Mood Disorder Market.

DUBLIN, Ireland -- Title: Converging market stimulators and inhibitors may cause a market decline of 13.6% by 2012 in the mood disorder market.

Dublin: Research and Markets (http://www.researchandmarkets.com/reports/c28595 ) has announced the addition of Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012 to their offering

Examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.

Objectives of the Report

The objectives of this report are to provide a detailed analysis of the global

psychopharmacotherapeutic market related to mood disorders and cognitive impairment. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

** Please note this report is delivered in pdf format which cannot be printed. For further information on ordering a pdf version which can be printed, please click enquire before buying

CONTENTS
List of Tables
List of Figures
Executive Summary
Objectives of the Report
Research Methodology
Chapter 1 Introduction to Mood Disorders and Cognitive Impairment
Chapter 2 The Global Market for Mood Disorders: Depression and Anxiety
Chapter 3 Drugs in Research and Development
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
Chapter 5 Report Synopsis
Bibliography and Reference Sources

Summary

Psychopharmacotherapies prescribed for mood disorders account for approximately 26% of the world CNS market. This mature market sector is estimated at US$17.4 billion for 2005 but is forecast to decrease 13.6% to US$15 billion by 2012. There are several reasons for a predicted downward shift in product revenues which, according to Spectra, includes patent expirations of leading antidepressants over the next 7 years, increased worldwide generic substitution, safety concerns over SSRIs; and cost containment in prescribing. However, major revenue losses for some products will be offset by the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance.

Generics companies are showing signs of increasing litigious activity in the antidepressant domain and loss of market exclusivity either through natural patent expiry or unsuccessful patent litigation are continuing to be major obstacles facing research-based companies. However, generic defense strategies for research-based companies may be transitioning to partnering with rather than opposing generic firms.

Despite challenges for the pharmaceutical industry in relation to centrally acting drugs to treat depressive disorders, novel drugs such as Valdoxan that offer unique advantages over other antidepressants in addition to positive effects on circadian rhythms show great promise for high value and volume sales on approval and launch. With over 80 drugs in development for depressive illnesses and cognitive impairment comprising sophisticated reuptake inhibitors, neuropeptide agonists, antagonists, and receptor modulators, the future of this psychopharmacology sector is predicted to transition to a highly changeable market segment that will lead to both winners and losers along the way.

Although a downward shift is forecast in market value for the global psychopharmacotherapeutic market in relation to mood disorders, several opportunities are identified including treatment-resistant depression and cognitive impairment. In particular, age-related cognitive decline is an untapped neuropsychological area that has been flagged by Spectra as a potential blockbuster market of the future. Drugs to prevent cognitive impairments such as forgetfulness, treat impairments in thought-processing or improve cognitive function such as memory or learning are a new focus of drug development that may not be restricted to neurodegenerative diseases, and successful commercialization with indications also in the life enhancement realm may expand the CNS market considerably over the next decade and beyond.

In this report, Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012, the reader will be introduced to CNS therapy areas of depressive disorders and cognitive impairment that are identified as highly dynamic market sectors that will continue to evolve over the next decade based on new antidepressants, line extensions, and

newly created indications and market sectors.

The report provides a detailed analysis of the therapy areas to include insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage antidepressants. Therapy area segments conclude with a summary of the key issues that are considered to affect growth and sustainability. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development. Promising agents are discussed in relation to development status and commercial prospects.

Therapy area forecasting and illustrative market data and analysis is also presented to provide an insight into top-performing products and sales estimates to 2012. Therapy forecasting to 2020 is also presented to enable the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modeling.

For more information visit http://www.researchandmarkets.com/reports/c28595